EXTEND-TNK Registry, IV Tenecteplase, Acute Ischemic Stroke, China

The EXTEND-TNK Registry (NCT07536165) was registered on ClinicalTrials.gov as an observational cohort study. The study will evaluate the effectiveness and safety of intravenous tenecteplase administered beyond 4.5 hours post last known well in acute ischemic stroke patients across multiple centers in China.

Affected parties including pharmaceutical companies, healthcare providers, and clinical investigators should note this registry represents an observational study of an existing approved drug (tenecteplase) in a new treatment window. Results may inform future stroke treatment protocols and potentially expand the acceptable time window for thrombolytic therapy.